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Abstract 
Breast cancer is the most common cancer among women worldwide. Breast cancer metas-
tasis primarily happens through lymphatic system, where the extent of lymph node metastasis 
is the major factor influencing staging, prognosis and therapeutic decision of the disease. We 
aimed to study the protein expression changes in different N (regional lymph nodes) stages of 
breast cancer. Protein expression profiles of breast cancerous and adjacent normal tissues 
were mapped by proteomics approach that comprises of two-dimensional polyacrylamide gel 
electrophoresis (2D-PAGE) and tandem mass spectrometry (LC-MS/MS) analysis. Calreticulin 
and tropomyosin alpha 3 chains were the common up-regulated proteins in N0, N1 and N2 
stages of breast cancer. Potential biomarker for each N stage was HSP 70 for N0, 80 k protein 
H precursor and PDI for N1 stage while 78 kDa glucose-regulated protein was found useful 
for N2 stage. In addition, significant up-regulation of PDI A3 was detected only in the me-
tastasized breast cancer. The up-regulation expression of these proteins in cancerous tissues 
can potentially use as indicators for diagnosis, treatment and prognosis of different N stages of 
breast cancer. 
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Introduction 
Breast cancer is a malignant disease originated 
from  breast’s  cell,  where  it  usually  forms  from  the 
terminal duct-lobular unit that supplies milk [1]. In 
2008,  460,000  deaths  due  to  breast  cancer  were  re-
ported worldwide [2].  
Infiltrating ductal carcinoma (IDC) is the  most 
common and aggressive type of breast cancer [3]. It is 
originated in the lactiferous duct, where it can break 
through  the  duct  tube  and  invade  or  infiltrate  the 
surrounding breast tissue, it can also spread to other 
parts of the body through lymph and blood systems 
[4].  
Metastasis  is  defined  as  the  process  by  which 
tumor  cells  spread  from  primary  tumor  site  to  sec-
ondary site (nearby or distant organ) and proliferate. 
Metastasis can occur through blood or lymph node 
[5].  In  breast  cancer,  metastasis  primarily  happens 
through  the  lymphatic  system  [6].  The  extent  of 
lymph node (N) metastasis is the major factor influ-
encing  staging  and  prognosis  of  most  malignancies 
and often determines therapeutic decision [7]. There-
fore, we aimed to study protein expression changes of 
N  stages  of  IDC  breast  tissues  as  classified  by  the 
TNM staging system, where emphasis will be given to 
the up-regulated proteins in cancerous tissues. Protein 
expression profiles for breast cancerous and its adja-
cent  normal  tissues  were  mapped  by  using  prote-
omics  approach.  We  hoped  to  identify  biomarkers 
Ivyspring  
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that can be used as diagnostic or therapeutic markers 
for different stages of breast cancer. 
Materials and methods 
Tissue collection: Human ethical approval was 
obtained  from  the  Human  Ethical  Clearance  Com-
mittee  of  Universiti  Sains  Malaysia  (USM)  and  the 
Ministry  of  Health  Malaysia.  Patient  consents  were 
obtained from the patients or their next of kin before 
collection  of  tissue  specimens.  Thirty-eight  pairs  of 
breast  tissues  comprised  of  normal  and  cancerous 
tissues were collected from Penang General Hospital 
(GH) after being confirmed as normal and cancerous, 
respectively by hospital pathologist. The tumor type 
used was IDC. There were 13 patients in N0 stage, 13 
patients in N1 stage and 12 patients in N2 stage ac-
cording  to  the  TNM  staging  system  (Table  1).  The 
patients  did  not  receive  any  preoperative 
neo-adjuvant chemotherapy or radiotherapy prior to 
surgery.  
 
Table 1. Basic information of all patients. 
Variables  No. of patient 
Age   
 36-45  6 
 46-55  7 
56-65  14 
66-75  8 
76-85  3 
Tumor origin   
 Right breast  20 
 Left breast  18 
Lymph Node Staging   
 0  13 
 1  13 
 2  12 
 
 
Tissue  processing:  The  tissue  specimens  were 
stored frozen at -80°C until analysis. Prior to protein 
extraction, tissues were thawed to room temperature 
and then rinsed thoroughly with distilled water. Fat 
tissues were removed from the tissue specimens and 
the specimens were cut into small pieces and trans-
ferred to microcentrifuge tubes. 
Protein extraction: An amount of 250 mg of tis-
sue was subjected to sequential extraction using Tris 
Buffer (TRIS) and Thiourea Lysis Buffer (TLB). First, a 
volume of TRIS (40 mM Tris, 1 mM protease inhibitor 
and 2 mM benzonase) was added to the tissue in a 
microcentrifuge  tube following a ratio  of 1:2; tissue 
(weight):  buffer  (volume).  The  tissue  was  then  dis-
rupted on ice for 10 minutes using a plastic homoge-
nizer. The lysate was vortex for 30 seconds and cen-
trifuged at 13000 rpm for 15 minutes at 4°C. The su-
pernatant was recovered and kept at -80°C for other 
analysis. Subsequently, 250 μL of TRIS was added to 
the remaining pellet and vortex briefly. The mixture 
was then centrifuged at 13000 rpm for 15 minutes at 
4°C. The supernatant was discarded. TLB [8 M Urea, 2 
M  Thiourea,  4%  (w/v)  3-[(3-Cholamidopropyl) 
dimethylammonio]-1-propanesulfonate  (CHAPS), 
0.4% (w/v) carrier ampholyte, 50 mM DTT and 1 mM 
AEBSF] was added to the remaining pellet following a 
ratio of 1:1 pellet (weight): buffer (volume). The mix-
ture  was  mixed  thoroughly  by  brief  vortexing  and 
centrifuged at 13000 rpm for 15 minutes at 4°C. After 
centrifugation, the supernatant was collected in a mi-
crocentrifuge  tube  and  subjected  to  protein  concen-
tration  determination  using  RC-DC  protein  assay 
(Bio-Rad, USA), 
Two-dimensional  polyacrylamide  gel  electro-
phoresis (2D-PAGE): This method was implemented 
by O’Farrell (1975) and Klose (1975). 150 ug of lysate 
in  125  µL  TLB  buffer  containing  trace  amount  of 
Bromophenol Blue was passively rehydrated unto a 
7cm  4-7  immobilized  pH  gradient  (IPG)  strip 
(Bio-Rad,  USA)  for  15  hours,  this  was  followed  by 
isoelectric focusing (IEF) using an IEF Cell (Bio-Rad, 
USA) in a linear ramping mode, starting from 0 to 200 
V  for  15  minutes,  followed  by  200  to  4000  V  for  2 
hours  and  hold  at  4000  V  until  7000  V-hr  was 
achieved.  After  focusing,  the  IPG  strip  was  treated 
with equilibration buffer I (6 M urea, 0.375 M Tris pH 
8.8, 2% SDS, 20% glycerol, and 2% DTT) and subse-
quently with equilibration II (6 M urea, 0.375 M Tris 
pH 8.8, 2% SDS, 20% glycerol, and 2.5% iodoacetam-
ide).  The  second  dimension  separation  was  carried 
out on 10% SDS-PAGE using a constant voltage of 200 
V  throughout  the  run.  The  gel  was  stained  using 
Bio-SafeTM  Colloidal  Coomasie  Blue  G-250  Stain 
(Bio-Rad, USA) and destained with deionized water.  
Image  analysis:  All  2D  images  were  captured 
using VersaDoc Imaging System (Bio-Rad, USA) and 
analyzed  using  PDQuest  Software  version  7.3 
(Bio-Rad, USA). Match sets consisted of 2D-gel imag-
es of protein extracts from normal and cancerous tis-
sues of the same patient were created. The common 
and  differentially  expressed  protein  spots  between 
normal  and  cancerous  tissues  were  compared  and 
identified. Normalization was applied to all the cap-
tured gel images, using this device, the intensity of 
every protein spots were measured as proportion to 
the  total  density  of  valid  spots.  Wilcoxon Int. J. Biol. Sci. 2012, 8 
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paired-sample test was used to determine the statis-
tical significance in the difference in intensity between 
protein spots from normal and cancerous tissues. 
In-gel digestion: All targeted protein spots were 
subjected to in-gel digestion according to Gam et al. 
(2003). It is a sample preparation procedure prior to 
LC-MS/MS analysis. Spots containing proteins were 
excised from gel and rinsed thoroughly with deion-
ized water to remove excess SDS. The gel pieces were 
washed  with  100  mM  ammonium  bicarbonate 
(NH4HCO3) for 10 minutes. The buffer was discarded. 
Acetonitrile (ACN) was added onto the gel pieces for 
dehydration purpose and discarded after 5 minutes 
incubation.  Then,  the  gel  pieces  were  subjected  to 
vacuum  centrifugation  (Eppendorf,  Germany)  until 
dried. These steps were repeated four times. Then, 15 
μL of 10 ng/μL trypsin prepared in digestion buffer 
(50 mM NH4HCO3, 5 mM CaCl2) was added to the gel 
pieces and incubated on ice for 45 minutes. The excess 
digestion buffer containing trypsin was discarded and 
10 μL of digestion buffer without trypsin was added 
and incubated at 37°C overnight. After centrifugation 
at 2000 rpm for 2 minutes at room temperature, the 
supernatant were collected and kept in microcentri-
fuge tube. Subsequently, 15 μL of 20 mM NH4HCO3 
was added to the gel pieces and incubated at room 
temperature  for  10  minutes.  The  supernatant  was 
collected and pooled with the previous collection after 
a brief spin. Then, the remaining peptides were fur-
ther  extracted  using  four  repeated  extraction  cycles 
using 5% (v/v) formic acid in 7:3 ACN: dH2O. In each 
cycle, gel pieces were incubated for 20 minutes in the 
buffer and spun down. All the supernatants recovered 
were pooled with the previous collections. The pooled 
peptide  extracts  were  evaporated  until  dried  using 
continuous flow of nitrogen gas. 
Reverse  phase  high  performance  liquid  chro-
matography  and  tandem  mass  spectrometry 
(LC-MS/MS): The peptides were reconstituted in 30 
µL  of  0.1%  (v/v)  formic  acid  in  85:15  solution  of 
dH2O: ACN. The mixture was briefly spun and the 
supernatant  was  recovered  and  transferred  into  a 
polypropylene vial insert and placed in autosampler 
of a HPLC system. A sample volume of 15 µL was 
injected into the enrichment column (Zorbax SB C18, 
35 X 0.5 mm, particle size 5 µm) at an isocratic flow 
rate of 0.05 mL/min using a binary pump HPLC 1100 
Series  (Agilent,  Germany).  The  mobile  phase  was 
0.1% (v/v) formic acid in 97:3 dH2O: ACN. Then, the 
concentrated peptides were eluted and transferred to 
a reverse phase column (Zorbax 300SB C18, 150 X 0.3 
mm, particle size 5 µm) by using a capillary pump 
operated at flow rate of 4 µL/min. The peptides were 
eluted  at  a  linear  gradient  of  5%  B  to  95%  B  in  70 
minutes and held constant at 95% B for 5 minutes. 
Mobile phase A was 0.1% (v/v) formic acid in deion-
ized water while mobile phase B was 0.1% (v/v) for-
mic  acid  in  ACN.  The  HPLC  was  interfaced  to  an 
electrospray ionization (ESI)-ion trap mass analyzer. 
The MS data was acquired through data dependent 
analysis  method  consisted  of  full  scan  MS  and 
MS/MS scan. The eluted peptides from HPLC were 
ionized by ESI operating in positive ion mode. The 
two most intense positively charged ions in every MS 
scan  that  exceeded  the  minimum  threshold  of  3000 
counts were isolated and excited to MS/MS scan. In 
MS/MS scan, the peptide was subjected to collision 
induced dissociation (CID) to produce MS/MS spec-
trum.  The  MS  parameters  used  were:  dry  gas  flow 
rate of 6 L/min, dry gas temperature of 300ºC, nebu-
lizer gas flow rate of 15 L/min and nebulizer pressure 
of 15.0 psi. The MS/MS analysis was performed with 
these parameters: collision energy at 1.15 V, capillary 
voltage  of  3.5  kV,  exit  capillary  voltage  of  84.5  V, 
skimmer 1 voltage of 17.2 V, skimmer 2 voltages at 6.0 
V, scan range of 200-1800 m/z with a scan time of 1 
second,  charge  state  of  2,  and  isolation  width  of  2 
m/z.  
Protein  identification:  The  MS/MS  data  ob-
tained was used to interrogate the identity of protein 
through Mascot Protein Database (MSDB) search en-
gine.  The  parameters  used  were  Homo  sapiens  for 
taxonomy,  trypsin  for  enzyme,  carboxymethyl  for 
fixed modification. The peptide tolerance and MS/MS 
tolerance were +/- 2 Da and 0.8 Da, respectively. The 
instrument type was set as ESI-TRAP and only one 
missed  cleavage  was  allowed.  The  function  and 
characteristic  of  proteins  were  obtained  from 
Swiss-Prot  (www.expasy.org)  and  NCBI 
(www.ncbi.nlm.nih.gov)  protein  database.  The  pro-
tein name, score, molecular weight (MW), isoelectric 
point (pI), and sequence coverage (seq. cov) were ob-
tained  through  MASCOT  Protein  Database  (MSDB) 
search  engine  (www.matrixscience.com).  The 
Swiss-Prot number was obtained through NCBI blast 
(www.ncbi.nlm.nih.gov).  The  grand  average  of  hy-
dropathy  (GRAVY)  was  obtained  through  Expasy 
proteomic  server  (expasy.org).  GRAVY  is  a  value 
calculated by sum of the hydropathy value for each 
amino  acid  and  dividing  by  number  of  residue  in 
protein sequence. It ranged from -4 to +4, where the 
more  positive  value  means  the  protein  is  more  hy-
drophobic  and  vice  versa  for  protein  with  negative 
value  [8].  The  function  of  proteins  was  obtained 
through www.uniprot.org. 
Western Blot: Western blotting was performed 
according to Towbin et al., (1979) with modifications. 
The tissue extract was separated using SDS-PAGE at Int. J. Biol. Sci. 2012, 8 
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constant voltage of 200 V. After SDS-PAGE, the gel 
was soaked in cold transfer buffer [25 mM Tris, 192 
mM Glycine, 1.3 mM SDS and 20% (v/v) methanol] 
for  30  minutes  while  nitrocellulose  membrane  and 
blotting papers of 8.0 x 7.4 cm in size (Bio-Rad, USA) 
were soaked in transfer buffer for 1 hour. The pore 
size  of  nitrocellulose  membrane  was  0.45  µm. 
Semi-dry  blotting  method  (Lauriere,  1993)  was  ap-
plied  using  TE  Semiphor  semi-dry  transfer  unit 
(Hoefer Scientific, Germany). The transfer of proteins 
from gel to nitrocellulose membrane was conducted at 
134 mA for 1.5 hours. After this, the membrane was 
rinsed  with  washing  buffer  [0.1%  (w/v)  BSA,  0.1% 
(v/v) Tween 20 in PBS] and blocked with blocking 
buffer [3% (w/v) BSA, 0.1% (v/v) Tween 20 in PBS] 
with gentle agitation for 2 hours at room temperature. 
The blocking buffer was discarded and the membrane 
was  washed  three  times  with  washing  buffer.  The 
membrane was then incubated with primary antibody 
overnight  at  4ºC  with  gentle  agitation.  This  is  fol-
lowed by incubation with secondary antibody for 2 
hours at room temperature after being washed three 
times with washing buffer. The membrane was incu-
bated  with  substrate  solution  containing 
5-bromo-4-chloro-3-indolyl  phosphate  (Bio-Rad, 
USA) with gentle shaking for 15 minutes in order to 
visualize the interaction between targeted protein and 
its antibody (primary antibody).  
 
Result 
In this study, a total of 38 pairs of normal and 
cancerous  breast  tissues  were  subjected  to  identical 
protein  extraction  and  2D-PAGE  procedures.  All 
2D-images were analyzed using gel image analyzer. 
Table 1 shows basic information of all patients. 
Inconsistent  expression  of  a  few  proteins  be-
tween patients was observed although a general con-
sistent pattern of proteomes can be identified within 
normal  and  cancerous  tissues,  respectively.  Hence, 
only  the  protein  spots  that  were  consistently  ex-
pressed in greater than 80% of all patients in the same 
cohort were considered as valid protein spot. Using 
this approach, we hoped to minimize the identifica-
tion  of  invalid  protein  spots  that  may  result  from 
variation between gels or error in the image analysis. 
The consistently expressed protein is more likely to be 
involved in the process of transformation of normal 
cell into cancer cells. A protein spot was categorized 
as  up-regulated  when  the  intensity  of  the  spot  in 
cancerous tissue is at least 2 folds or greater than that 
of  normal  tissue.  The  vice-versa  was  applied  to 
down-regulated  proteins.  A  protein  was  termed  as 
up-regulated  protein  when  it  showed  consistent 
up-regulation characteristic  in greater than  65% pa-
tients in the cohort. The similar was applied to the 
down-regulated proteins.  
 Sixty-four valid protein spots on 2D gel images 
of TLB extracts of breast tissues were detected.  The 
protein  spots  that  showed  consistent  differentially 
expressed in >65% patients were subjected to in-gel 
digestion, LC-MS/MS analysis and MASCOT search. 
Figure 1 shows the up- and down-regulated protein 
spots on 2D gel image of a TLB extract from breast 
cancerous  tissue.  An  example  of  MS  and  MS/MS 
spectrum of calreticulin are shown in Figure 2. The 
identities and characteristics of the significant up- and 
down-regulated proteins are shown in Table 2. 
 
Table 2. List of up and down-regulated proteins detected in TLB extract. 
No  Protein Name  Swiss-prot 
No 
Score  MW  pI  Seq 
Cov 
GRAVY  Function* 
Up-regulated 
proteins 
               
1  Calrecticulin  P27797  175  46890  4.3  18%  -1.104  Molecular calcium-binding chaperone 
2  80 k protein H precursor  P14314  134  60245  4.34  17%  -0.910  Protein kinase C binding 
3  Tropomyosin alpha-3 
chain 
P06753  55  32857  4.68  4%  -1.051  Regulates muscle contraction, stabilizes 
cytoskeleton actin filaments 
4  Tropomyosin isoform  P09493  104  28519  4.89  14%  -1.044  Regulates muscle contraction, stabilizes 
cytoskeleton actin filaments 
5  Protein disulfide iso-
merase (PDI) 
P07237  45  57487  4.76  19%  -0.431  Catalyzes the formation, breakage and 
rearrangement of disulfide bonds 
6  Heat shock protein 90 
(HSP 90) 
Q4R250  48  92572  4.77  10%  -0.719  Molecular chaperone that functions in the 
processing and transport of secreted pro-
teins 
7  Tubulin, beta polypep-
tide 
Q91575  161  48142  4.7  15%  -0.355  Major constituent of microtubules 
8  78 kDa glu-
cose-regulated protein 
P11021  505  72404  5.07  37%  -0.487  Anti-apoptosis, cellular response to glu-
cose starvation 
9  Heat shock protein 60  P10809  50  61348  5.7  17%  -0.076  Implicated in mitochondrial protein im-Int. J. Biol. Sci. 2012, 8 
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(HSP 60)  port and macromolecular assembly 
10  Heat shock 70 kDa pro-
tein 8 isoform 1 (HSP 70) 
P11142  220  71087  5.28  17%  -0.456  Molecular chaperone 
11  Heat shock 70 kDa pro-
tein 1 
Q5R7D3  257  69982  5.48  14%  -0.383  Stabilize preexistent proteins against 
aggregation and mediate the folding of 
newly translated polypeptides in the 
cytosol and within organelles 
 
12  Protein disulfide iso-
merase A3 (PDI A3) 
P30101  581  57167  5.98  21%  -0.506  Catalyzes the rearrangement of disulfide 
bonds in proteins 
Down-regulated 
protein 
 
               
13  Tubulin alpha-1 chain  Q6P9V9  235  50816  4.94  28%  -0.23  Major constituent of microtubules 
*Functions were obtained from www.uniprot.org. 
 
 
Figure 1. 2D gel images of TLB extracts: (i) breast normal tissue, (ii) breast cancerous tissue of the same patient. The 
white arrow denoted the landmark used in gel image analysis. Brown circles denoted the up-regulated proteins. Blue circled 
denoted the down-regulated protein. The spot number was labeled accordingly to protein list in Table 2. Int. J. Biol. Sci. 2012, 8 
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Figure 2. MS analysis for calreticulin; MS spectrum, MS/MS spectrum and the amino acid sequence for peptide derived 
from the MS/MS spectrum. 
 
Twelve proteins were identified as up-regulated 
proteins and one protein as down-regulated protein 
in our study (Table 2). The protein name, score, mo-
lecular weight (MW), isoelectric point (pI), sequence 
coverage (seq. cov) and function were indicated in the 
table. Table 3 shows protein expression profiles and 
average fold change of these proteins in patients suf-
fered from N0, N1 and N2 stages breast cancer, re-
spectively. There were three up-regulated proteins in 
N0 stage, namely calreticulin (77%), tropomyosin al-
pha-3 chain (69%) and HSP 70 (69%). Tubulin alpha-1 
chain was down-regulated in N0 stage. A total of ten 
proteins were up-regulated in N1 stage, these proteins 
were  calreticulin  (92%),  80  k  protein  H  precursor 
(85%), tropomyosin alpha-3 chain (77%), tropomyosin 
isoform (69%), PDI (77%), HSP 90 (69.23%), tubulin, 
beta polypeptide (69%), HSP 60 (85%), heat shock 70 
kDa protein 1 (69%) and PDI A3 (69%). Five proteins 
were  up-regulated  while  one  protein  was 
down-regulated in N2 stage. The up-regulated pro-
teins  were  calreticulin  (83%),  tropomyosin  alpha-3 
chain (75%), 78 kDa glucose-regulated protein (75%), 
HSP  60  (67%)  and  PDI  A3  (92%).  Tubulin  alpha-1 
chain  (67%)  was  down-regulated  in  N2  stage.  The 
change in protein expression of all these proteins were 
statistically  significant  at  a  95%  confidence  level 
(p<0.05) as  analyzed  using  Wilcoxon  paired-sample 
test. 
The protein identity as identified by LC-MS/MS 
and MASCOT database search engine was validated 
using  Western  blot  experiments.  All  the  potential 
biomarker  with  commercially  available  antibodies 
were subjected to this analysis, these biomarkers in-
cluded  calreticulin,  PDI  A3,  HSP  60  and  HSP  70, Int. J. Biol. Sci. 2012, 8 
 
http://www.biolsci.org 
359 
where the identify of all of these proteins were con-
firmed  by  Western  blotting.  Figure  3  shows  the 
Western  blot images for calreticulin and PDI A3 in 
breast normal and cancerous extracts from the same 
patient while beta-actin was used as an internal con-
trol. The higher intensity of antigen- antibody inter-
action  for  calreticulin  and  PDI  A3  was  observed  in 
cancerous  tissue  compared  to  normal  tissue,  which 
may indicate the higher expression of these proteins 
in cancerous tissue. 
 
Table 3. Protein expression percentage and fold change in N0, N1 and N2 stages of breast cancer. 
 
Protein Name  N stage  Up-regulated (%)  Down-regulated 
(%) 
Same expression (%)  Not detected 
(%) 
Fold change 
Calrecticulin  N0  77  8  15  0  + 4.33 
N1  92  0  8  0  + 8.74 
N2  83  17  0  0  + 3.04 
80 k protein H precursor  N0  62  8  30  0  + 3.80 
N1  84  8  8  0  + 5.48 
N2  50  17  0  33  + 2.20 
Tropomyosin alpha-3 chain 
 
N0  69  0  8  23  + 6.01 
N1  77  0  15  8  + 11.36 
N2  75  8  9  8  + 5.75 
Tropomyosin isoform 
 
N0  62  0  31  7  + 3.67 
N1  69  8  15  8  + 3.69 
N2  50  8  25  17  + 1.58 
PDI 
 
N0  54  0  46  0  + 3.31 
N1  77  0  15  8  + 5.19 
N2  50  17  25  8  + 1.63 
HSP 90 
 
N0  46  8  46  0  + 1.66 
N1  69  8  15  0  + 4.20 
N2  58  25  17  0  + 2.13 
Tubulin, beta polypeptide  N0  54  8  38  0  + 2.20 
N1  69  0  31  0  + 3.21 
N2  50  8  34  8  + 1.38 
Tubulin alpha chain  N0  0  23  69  8  - 1.39 
N1  8  39  46  7  -1.65 
N2  8  67  25  0  -2.57 
78 kDa glucose-regulated 
protein 
N0  54  15  31  0  + 1.34 
N1  54  0  46  0  + 2.69 
N2  75  17  8  0  + 2.28 
HSP 60 
 
N0  54  8  38  0  + 3.27 
N1  85  0  15  0  + 4.85 
N2  67  17  17  0  + 3.50 
HSP 70 
 
N0  69  0  31  0   + 2.25 
N1  54  0  46  0  + 1.93 
N2  42  0  58  0  + 1.39 
Heat shock 70 kDa protein 1  N0  46  23  31  0  + 1.25 
N1  69  8  23  0  + 2.18 
N2  42  33  25  0  + 1.38 
PDI A3  N0  54  15  31  0  + 2.24 
N1  69  15  15  0  + 3.44 
N2  92  8  0  0  + 2.80 Int. J. Biol. Sci. 2012, 8 
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Figure 3. Western Blot images of beta-actin (45kDa), calreticulin (48kDa) and PDI A3 (56.8kDa) from breast normal and 
cancerous tissues. 
 
Discussion 
 TNM  staging  is  determined  according  to  the 
outcomes  of  physical  examination,  biopsy,  and  im-
aging  tests  [7].  It  is  useful  to  guide  physicians  in 
treatment option and prognosis of patients [9]. In this 
study, we focused on the protein expression changes 
in N0, N1 and N2 stages of breast cancer. Due to lim-
itation in sample size, N3 stage was not included in 
our study. 
 TLB buffer made up of thiourea, urea and other 
reagents that favor the extraction of membrane asso-
ciated  or  membrane  proteins  was  used  to  extract 
proteins from the tissue pellet that was subjected to 
prewashing with TRIS buffer for removal of hydro-
philic proteins. Thirty percent of human proteome is 
consisted  of  membrane  proteins  [9],  these  proteins 
involve in various biological processes of cell, which 
include signal transduction, immune regulation and 
transportation  [10].  In  addition,  the  nature  of  these 
proteins of being membrane associated making them 
good target for recognition in drug-targeted therapy 
for treatment of cancers.  
 In general, the differentially expressed proteins 
identified  in  this  study  can  be  grouped  as  either 
common proteins in all stages or predominant protein 
for each stage. The common proteins can be poten-
tially used as biomarkers for diagnosis or treatment 
for all N stages. On the other hand, the predominant 
protein in each stage may be collectively used with 
other diagnoses for classification of N staging. Two 
common proteins that were up-regulated in all stages 
were  calreticulin  and  tropomyosin  alpha  3  chain. 
Calrecticulin was a very promising biomarker in view 
of its high expression consistency in most of the pa-
tients, where it was up-regulated significantly at 77%, 
92% and 83% in N0, N1 and N2 stages, respectively.  
 Calreticulin  was  first  introduced  by  Ostwald 
and MacLennan in 1974 [11]. It is a Ca2+ binding pro-
tein that localizes in the peripheral membrane of lu-
men of ER and nuclear envelope. It is important for 
Ca2+ storage, signaling and regulation in ER [12]. As 
reviewed by Michalak et al., (1999), calreticulin is also 
a lectin-like chaperone that involves in the synthesis 
of a variety of molecules, such as ion channels, surface 
receptors, intergrins and transporters. It helps to in-
crease the yield of correctly folded proteins and pre-
vents the aggregation and assembly of partially fold-
ed  proteins.  It  had  been  reported  as  potential  bi-
omarker for breast cancer correlated with postopera-
tive metastasis [13, 14].  
 Tropomyosin  alpha  3  chain  was  up-regulated 
significantly at 69%, 69% and 75% in N0, N1 and N2 
stages, respectively. Tropomyosins (Tms) are family 
of  microfilament-associated  structural  proteins 
[15-17]. The expression change of Tms was induced by 
variety  of  carcinogens  including  chemical  carcino-
gens,  UV  radiation,  DNA  and  RNA  tumor  viruses 
during cancer cell transformation. Tropomyosin alpha 
3 chain (Tm-3) is HMW (high molecular weight with 
284  amino  acids)  Tms.  In  contrary  to  our  finding, 
HMW  Tms  was  reported  down-regulated  in  breast 
cancer  and  bladder  cancer  although  it  was 
up-regulated in CNS tumors [15]. 
 The  protein  that  predominantly  up-regulated 
(69%) in N0 stage was HSP 70, HSP 70 is a member of 
heat shock family that was induced under stress en-
vironment. It is function as ATP-dependent molecular 
chaperone [18, 19] that interacts with unfolded poly-
peptide sequences during mRNA translation to pre-
vent premature self-association in nascent protein. It 
also assists in transportation of proteins across cellu-
lar  membranes  and  targeting  protein  for  lysosomal 
degradation [19]. HSP 70 was reported up-regulated 
in breast cancer [20]. 
 When comparing to other stages, N1 stage has 
the  highest  number  of  predominantly  up-regulated 
proteins, namely 80 k protein H precursor, tropomy-
osin isoform, PDI, HSP 90 (or also known as tumor 
rejection antigen), tubulin, beta polypeptide and heat 
shock 70 kDa protein 1. Amongst these, 80 k protein H 
precursor was the most consistent up-regulated pro-
tein in N1 stage, where it was found up-regulated at 
85%. This is followed by PDI at 76.9% while the rest of 
the proteins were up-regulated at 69%. Therefore, we 
foresee the usefulness of 80 k protein H precursor and 
PDI  as  promising  markers  that  can  be  collectively 
used to indicate N1 stage of breast cancer. 80 k protein Int. J. Biol. Sci. 2012, 8 
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H precursor or also known as glucosidase 2 subunit 
beta,  is  a  substrate  for  protein  kinase  C  [21].  It  in-
volves in the mechanism of elevated fibroblast growth 
factor-1 (FGF-1) in breast cancer [22], where FGF-1 is 
one of the key factors in angiogenesis and lymphan-
giogenesis in cancer [23]. On the other hand, PD1 is an 
enzyme that catalyzes the formation, reduction and 
isomerization of protein disulfide bond in ER [24, 25], 
where it functions as molecular chaperone by assist-
ing in protein folding. Hence, it plays a critical role in 
the  maintenance  of  protein  structural  stability  and 
functional  integrity  [26].  In  addition,  PDI  is  also 
known  as  intracellular  estrogen-binding  protein, 
which accumulates estrogen in cells and augment the 
activities of estrogen receptor-mediated transcription 
[24]. PDI was reported as a differentially expressed 
protein in IDC breast cancer [27]. 
 The predominantly up-regulated protein for N2 
stage  was  78  kDa  glucose-regulated  protein,  it  was 
significantly up-regulated at 75%. Its alternate name is 
immunoglobulin  heavy  chain  binding  protein  or 
“BIP”.  Similar  with  heat  shock  family  members,  it 
functions as molecular chaperone that assists in fold-
ing and assembly of newly synthesized proteins. Its 
expression is induced under glucose starvation [28]. It 
was reported up-regulated in breast cancer [29] and 
colorectal cancer [30]. 
 It  is  interesting  to  note  the  significant 
up-regulation of PDI A3 was only found in N1 and N2 
stages,  which  represent  the  breast  cancer  that  had 
metastasized. In addition, its extent of up-regulation 
expression in N2 stage is worth mentioning, where it 
was  up-regulated  significantly  at  91%  in  N2  stage 
while only at 69% in N1 stage. The up-regulation of 
PDI seems to be paralleled with the advancing of N 
stages (51% at N0 stage). We believe that PDI A3 may 
be used in the prognosis of breast cancer, where the 
presence of this protein may indicate the metastasize 
potential of breast cancer. PDI A3 is one of the mem-
bers of PDI family. The thiol-disulfide exidoreductase 
activity of PDI A3 catalyzes oxidation, reduction and 
isomerization  of  protein  disulfide  bond.  PDI  A3 
non-covalently  interacts  with  two  lectin  molecular 
chaperones known as calnexin and calreticulin. PDI 
A3 involves in the oxidation folding of newly synthe-
sized glycoproteins [25, 31, 32]. It was also reported 
up-regulated  in  gastric  cancer  [33]  and  pancreatic 
cancer [34]. 
Conclusion 
  In this study, we detected two proteins, namely 
calreticulin  and  tropomysin  alpha  3  chains  as  com-
mon up-regulated proteins in N0, N1 and N2 stages of 
breast cancer, while HSP 70, 80 k protein H precursor, 
PDI,  and  78  kDa  glucose-regulated  protein  were 
predominantly up-regulated proteins in N0, N1 and 
N2,  respectively.  On  the  other  hand,  the  increase 
up-regulation pattern of PDI A3 was parallel with the 
advancing N stages of breast cancer. By virtue of cel-
lular  location  of  membrane  proteins  in  cells,  their 
up-regulation  expression  in  cancerous  tissues  can 
potentially  use  as  indicators  for  diagnosis  or 
drug-targeted therapy of breast cancer, nevertheless, 
before all these potential biomarkers turn to be used 
in clinical applications, more retrospective and pro-
spective  clinical  trials  are  needed  to  evaluate  the 
overall  clinical  utility  of  these  indicators.  Further-
more,  the  significance  of  each  biomarker  for  breast 
cancer can be evaluated by using a greater number of 
tissue specimens. 
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